Cost-effectiveness of home non-invasive ventilation in patients with persistent hypercapnia after an acute exacerbation of COPD in the UK

Cost-effectiveness of home non-invasive ventilation in patients with persistent hypercapnia after an acute exacerbation of COPD in the UK

Home non-invasive mechanical ventilation (HMV) with home oxygen therapy (HOT) in patients with persistent hypercapnia following an acute exacerbation of chronic obstructive pulmonary disease delays hospital readmission. The economic impact of this treatment is unknown. We evaluated the cost-effectiv...

Full description

Saved in:
Bibliographic Details
Published in:Thorax Vol. 78; no. 5; p. 523
Main Authors: Murphy, Patrick Brian, Brueggenjuergen, Bernd, Reinhold, Thomas, Gu, Qing, Fusfeld, Laura, Criner, Gerard, Goss, Thomas F, Hart, Nicholas
Format: Journal Article
Language:English
Published: England 01-05-2023
Subjects:
Cost-Benefit Analysis
Humans
Hypercapnia - etiology
Hypercapnia - therapy
Noninvasive Ventilation
Pulmonary Disease, Chronic Obstructive
Quality of Life
Quality-Adjusted Life Years
Respiration, Artificial
Treatment Outcome
United Kingdom
United Kingdom
Health Economist
COPD Exacerbations
Non invasive ventilation
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Home non-invasive mechanical ventilation (HMV) with home oxygen therapy (HOT) in patients with persistent hypercapnia following an acute exacerbation of chronic obstructive pulmonary disease delays hospital readmission. The economic impact of this treatment is unknown. We evaluated the cost-effectiveness of HMV in the UK healthcare system using data from a previously published efficacy trial. Quality-adjusted life-years (QALYs) were computed from EQ-5D-5L. Accounting for all direct patient costs HOT-HMV was £512 (95%CI £36 to £990) more expensive per patient per year than HOT-alone. This small increase in cost was accompanied by increased quality of life leading to an incremental cost-effectiveness ratio of £10 259 per QALY. HOT-HMV was cost-effective in this clinical population. Trial registration number: NCT00990132.
ISSN:1468-3296
DOI:10.1136/thorax-2022-219653